These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 9923932)
1. Polysomies but not Y chromosome losses have prognostic significance in pTa/pT1 urinary bladder cancer. Neuhaus M; Wagner U; Schmid U; Ackermann D; Zellweger T; Maurer R; Alund G; Knönagel H; Rist M; Moch H; Mihatsch MJ; Gasser TC; Sauter G Hum Pathol; 1999 Jan; 30(1):81-6. PubMed ID: 9923932 [TBL] [Abstract][Full Text] [Related]
2. DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH. Sauter G; Gasser TC; Moch H; Richter J; Jiang F; Albrecht R; Novotny H; Wagner U; Bubendorf L; Mihatsch MJ Urol Res; 1997; 25 Suppl 1():S37-43. PubMed ID: 9079755 [TBL] [Abstract][Full Text] [Related]
3. Sex chromosome abnormalities in bladder cancer: Y polysomies are linked to PT1-grade III transitional cell carcinoma. Panani AD; Roussos C Anticancer Res; 2006; 26(1A):319-23. PubMed ID: 16475713 [TBL] [Abstract][Full Text] [Related]
4. Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. Krüger S; Mess F; Böhle A; Feller AC Int J Oncol; 2003 Jul; 23(1):41-8. PubMed ID: 12792774 [TBL] [Abstract][Full Text] [Related]
5. Progression to detrusor-muscle invasion in bladder carcinoma is associated with polysomy of chromosomes 1 and 8 in recurrent pTa/pT1 tumours. Watters AD; Going JJ; Grigor KM; Bartlett JM Eur J Cancer; 2002 Aug; 38(12):1593-9. PubMed ID: 12142047 [TBL] [Abstract][Full Text] [Related]
6. Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder. Watters AD; Ballantyne SA; Going JJ; Grigor KM; Bartlett JM BJU Int; 2000 Jan; 85(1):42-7. PubMed ID: 10619944 [TBL] [Abstract][Full Text] [Related]
9. Interphase cytogenetics of bladder cancer progression: relationship between aneusomy, DNA ploidy pattern, histopathology, and clinical outcome. Cianciulli AM; Bovani R; Leonardo F; Antenucci A; Gandolfo GM; Giannarelli D; Leonardo C; Iori F; Laurenti C Int J Clin Lab Res; 2000; 30(1):5-11. PubMed ID: 10984125 [TBL] [Abstract][Full Text] [Related]
10. DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH: prognostic implications. Cianciulli AM; Bovani R; Leonardo C; Iori F; Coletta AM; Marzano R; Antenucci A; Gandolfo GM; Laurenti C Eur J Histochem; 2001; 45(1):65-71. PubMed ID: 11411867 [TBL] [Abstract][Full Text] [Related]
11. Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder cancer. Pycha A; Mian C; Haitel A; Hofbauer J; Wiener H; Marberger M J Urol; 1997 Jun; 157(6):2116-9. PubMed ID: 9146595 [TBL] [Abstract][Full Text] [Related]
12. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805 [TBL] [Abstract][Full Text] [Related]
13. Decreased expression of KAI1 metastasis suppressor gene is a recurrence predictor in primary pTa and pT1 urothelial bladder carcinoma. Su JS; Arima K; Hasegawa M; Franco OE; Umeda Y; Yanagawa M; Sugimura Y; Kawamura J Int J Urol; 2004 Feb; 11(2):74-82. PubMed ID: 14706010 [TBL] [Abstract][Full Text] [Related]
14. Genetic aberrations of NAT2 and chromosome 8: their association with progression in transitional cell carcinoma of the urinary bladder. Watters AD; Stacey MW; Going JJ; Grigor KM; Cooke TG; Sim E; Bartlett JM Urol Int; 2001; 67(3):235-9. PubMed ID: 11598453 [TBL] [Abstract][Full Text] [Related]
15. Y chromosome loss is a frequent early event in urothelial bladder cancer. Minner S; Kilgué A; Stahl P; Weikert S; Rink M; Dahlem R; Fisch M; Höppner W; Wagner W; Bokemeyer C; Terracciano L; Simon R; Sauter G; Wilczak W Pathology; 2010 Jun; 42(4):356-9. PubMed ID: 20438408 [TBL] [Abstract][Full Text] [Related]
16. Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder? Bartlett JM; Watters AD; Ballantyne SA; Going JJ; Grigor KM; Cooke TG Br J Cancer; 1998 Jun; 77(12):2193-8. PubMed ID: 9649132 [TBL] [Abstract][Full Text] [Related]
17. Noninvasive detection of alterations in chromosome numbers in urinary bladder cancer cells, using fluorescence in situ hybridization. Okamura T; Umemoto Y; Yasui T; Saiki S; Kuroda H; Kotoh S; Kamizaki H Int J Clin Oncol; 2004 Oct; 9(5):373-7. PubMed ID: 15549587 [TBL] [Abstract][Full Text] [Related]
18. Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma. Hopman AH; Kamps MA; Speel EJ; Schapers RF; Sauter G; Ramaekers FC Am J Pathol; 2002 Oct; 161(4):1119-25. PubMed ID: 12368185 [TBL] [Abstract][Full Text] [Related]
19. Centrosome hyperamplification predicts progression and tumor recurrence in bladder cancer. Yamamoto Y; Matsuyama H; Furuya T; Oga A; Yoshihiro S; Okuda M; Kawauchi S; Sasaki K; Naito K Clin Cancer Res; 2004 Oct; 10(19):6449-55. PubMed ID: 15475431 [TBL] [Abstract][Full Text] [Related]
20. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder. Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]